Study of CAR-T Therapy in Older Patients
NCT04300998 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 154
Last updated 2026-04-07
Summary
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.
Conditions
- Lymphoma
- Refractory B-Cell Lymphoma
- Lymphoma, B-Cell
- DLBCL NOS
- High-grade B-cell Lymphoma
- Multiple Myeloma
Interventions
- BEHAVIORAL
-
Activities of Daily Living/ADLs
7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
- BEHAVIORAL
-
Instrumental Activity of Daily Living
8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
- BEHAVIORAL
-
Timed Up and Go
Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\<10 seconds, 10-20 seconds, \>20 seconds)
- BEHAVIORAL
-
Cognition
Mini-Cognition test: CDT and 3-word recall
- BEHAVIORAL
-
Geriatric Depression Scale
Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \>/=1 is usually indicative of depression.
- BEHAVIORAL
-
Social Support
Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
- BEHAVIORAL
-
Brief Test of Attention
assess selective auditory attention.
- BEHAVIORAL
-
Trail Making Test
Assesses visual scanning, graphomotor speed, and set shifting.
- BEHAVIORAL
-
Controlled Oral Word Association Test
A timed test of verbal fluency
- BEHAVIORAL
-
Hopkins Verbal Learning Test-Revised
The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
- OTHER
-
Blood draw
collection of blood tests
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Richard Lin, MD, PhD · Memorial Sloan Kettering Cancer Center
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-04
- Primary Completion
- 2027-03-04
- Completion
- 2027-03-04
Countries
- United States
Study Locations
More Related Trials
-
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
NCT06838832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT07022964 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
NCT05625594 ·Status: RECRUITING ·Phase: PHASE1
-
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
NCT04689659 ·Status: COMPLETED ·Phase: PHASE2
-
CAR T-CELL Therapy Educational Video Trial
NCT04280133 ·Status: UNKNOWN ·Phase: NA
-
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
NCT04488354 ·Status: COMPLETED ·Phase: PHASE1
-
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671 ·Status: RECRUITING ·Phase: PHASE2
-
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT06925464 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
NCT04555551 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
NCT06381830 ·Status: RECRUITING ·Phase: PHASE2
-
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
NCT06617286 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
NCT03262298 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT03602157 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
NCT03302403 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
NCT03097770 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
NCT01029366 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
NCT07055477 ·Status: RECRUITING ·Phase: PHASE1
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
NCT05672147 ·Status: RECRUITING ·Phase: PHASE1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
NCT06340737 ·Status: RECRUITING ·Phase: PHASE1
-
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
NCT05248685 ·Status: WITHDRAWN ·Phase: PHASE1
-
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
NCT06213636 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
NCT07093086 ·Status: WITHDRAWN ·Phase: PHASE1
-
CAR-T for Claudin18.2 Positive Solid Tumors
NCT07266311 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1